Cite
McDonough EM, Barrett CW, Parang B, et al. MTG16 is a tumor suppressor in colitis-associated carcinoma. JCI Insight. 2017;2(16)doi: 10.1172/jci.insight.78210.
McDonough, E. M., Barrett, C. W., Parang, B., Mittal, M. K., Smith, J. J., Bradley, A. M., Choksi, Y. A., Coburn, L. A., Short, S. P., Thompson, J. J., Zhang, B., Poindexter, S. V., Fischer, M. A., Chen, X., Li, J., Revetta, F. L., Naik, R., Washington, M. K., Rosen, M. J., Hiebert, S. W., Wilson, K. T., & Williams, C. S. (2017). MTG16 is a tumor suppressor in colitis-associated carcinoma. JCI insight, 2(16), . https://doi.org/10.1172/jci.insight.78210
McDonough, Elizabeth M, et al. "MTG16 is a tumor suppressor in colitis-associated carcinoma." JCI insight vol. 2,16 (2017). doi: https://doi.org/10.1172/jci.insight.78210
McDonough EM, Barrett CW, Parang B, Mittal MK, Smith JJ, Bradley AM, Choksi YA, Coburn LA, Short SP, Thompson JJ, Zhang B, Poindexter SV, Fischer MA, Chen X, Li J, Revetta FL, Naik R, Washington MK, Rosen MJ, Hiebert SW, Wilson KT, Williams CS. MTG16 is a tumor suppressor in colitis-associated carcinoma. JCI Insight. 2017 Aug 17;2(16). doi: 10.1172/jci.insight.78210. eCollection 2017 Aug 17. PMID: 28814670; PMCID: PMC5621889.
Copy
Download .nbib